enGene Holdings Inc.

NASDAQ:ENGN

Biotechnology

Healthcare
$1.72 -1.15%

-$0.02 today

Market cap
$115.27M
Beta
-0.29
P/E (TTM)
-1.8
EPS (TTM)
-$0.95
52W Low $1.40High $12.25

Volume 1.64M

Average 1.58M

ENGN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

enGene Holdings Inc.NASDAQ: ENGN

EBITDA · Q2 FY2026 · quarter ended Apr 2026

EBITDA remains negative

Q2 FY2026 EBITDA was -$31.79M, compared with -$24.74M a year earlier. Trailing-twelve-month EBITDA was -$125.94M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 8 analysts of $0 (+100.0%) for the fiscal year ending Oct 2026, a step up from the -118.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterApr 2026
-$31.79M-10.3% QoQ
Last fiscal yearOct 2025
-$113.8M-118.7% YoY
LTMApr 2026
-$125.94M-65.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.5%+100.0%+128.5 pp
1 year-118.7%+100.0%+218.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(113.8M) USD
Year-over-year change
-118.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ENGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -65.1% is the 9th highest of 10, against a peer median of -17.1%.
ENGN Competitors
EBITDA for ENGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026-$5.14M USD+92.4%—2.4%
CLLSCellectis S.A.LTM Mar 2026-$51.11M USD-57.3%—75.1%
ACIUAC Immune S.A.LTM Mar 2026-CHF 64.45M CHF-29.6%—1740.8%
ANROAlto Neuroscience, Inc.LTM Mar 2026-$71.29M USD-16.9%——
SLNSilence Therapeutics plcLTM Mar 2026-$78.13M USD——8478.5%
KRROKorro Bio, Inc.LTM Mar 2026-$78.15M USD+14.5%—2034.0%
ALTAltimmune, Inc.LTM Mar 2026-$88.27M USD+2.7%—245200.0%
ENGNenGene Holdings Inc.LTM Apr 2026-$125.94M USD-65.1%——
DBVTDBV Technologies S.A.LTM Mar 2026-$159.48M USD-49.1%——
LRMRLarimar Therapeutics, Inc.LTM Mar 2026-$165.68M USD-74.6%——
ANNXAnnexon, Inc.LTM Mar 2026-$193.41M USD-17.1%——
Peer median (excluding ENGN) —-17.1%—1887.4%

Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development12.46M15.47M16.46M38.32M94.48M
Selling, General & Admin3.16M3.26M8.47M23.98M28.69M
Operating Expenses15.87M19.43M26.06M62.3M123.17M
Depreciation & Amortization272K238K175K323K509K
EBITDA(18.15M)(22.78M)(94.77M)(52.04M)(113.8M)
EBITDA Margin—————
Operating Income(15.87M)(19.43M)(26.06M)(62.3M)(123.17M)
Operating Margin—————
Interest Income25K129K1.12M10.41M9.43M
Interest Expense5.02M1.42M4.95M2.8M2.99M
Other Income / Expenses(7.57M)(5.01M)(73.84M)7.14M5.86M
Income Before Tax(23.44M)(24.44M)(99.9M)(55.16M)(117.3M)
Pre-Tax Margin—————
Income Tax Expense022K17K(19K)0
Net Income(23.44M)(24.46M)(99.92M)(55.14M)(117.3M)
Net Margin—————
EPS (Basic)(0.01)0.00(4.24)(1.46)(2.29)
EPS (Diluted)(0.01)0.00(4.24)(1.46)(2.29)
Weighted Avg Shares15.81M15.81M23.56M44.64M51.12M
Weighted Avg Shares (Diluted)15.81M15.81M23.56M44.64M51.12M

enGene Holdings Inc.

NASDAQ:ENGN

Intrinsic Alpha fair value

Locked

Current Price

$1.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.